BRAINTREE, Mass., Aug. 8, 2016 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) today announced that Christopher Simon, President and CEO, has acquired 60,000 shares of the Company's common stock at an average price per share of $35.00. The acquisition of these shares was by open market purchases taking place during the last three business days.
Mr. Simon joined the Company as Chief Executive Officer effective May 16, 2016. Under the terms of his compensation agreement, the Company will match up to $2 million of his share purchases with an equal number of relative performance-based share units. The vesting and value of the share units are conditional upon Mr. Simon's continued employment with the Company and the achievement of three-year performance conditions established by the Company's compensation committee.
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative hematology products and solutions for our customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.
Gerry Gould, VP-Investor Relations
Sandra Jesse, Executive VP
SOURCE Haemonetics Corporation